Printer Friendly
The Free Library
5,667,542 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Takara Bio, Okayama University Jointly Confirm That Angelica Utilis Promotes Bone Formation and Increases Bone Mass.


Tokyo, Japan, July 4, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Takara Bio has elucidated a unique property of Angelica angelica (ănjĕl`ĭkə), any species of the genus Angelica, plants of the family Umbelliferae (parsley family), native to the Northern Hemisphere and New Zealand, valued for their potency as a medicament and protection against  Utilis, a kind of wild perennial herb known as Ashitaba, in collaboration with Okayama University Okayama University (岡山大学) is a national university located in Okayama, Japan.

The school was originally founded in 1870 and it was established as a university in 1949.
.

In the recent experiments using osteoporotic mice, the two partners observed how an intake of powder made of Angelica Utilis affects the condition of the mice.

The results indicated that the intake helps promote bone formation and increase bone mass in the mice. Accordingly, the two partners concluded that Angelica Utilis will be one of promising ingredients for the treatment of osteoporosis.

Details of the joint research will be presented at the 84th General Session & Exhibition of International Association for Dental Research The International Association for Dental Research(IADR) is a professional association that focuses on research in the field of dentistry. The aim of this association by constitution is to promote research in all fields of oral and related sciences, to encourage improvements in methods for .

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jul 4, 2006
Words:122
Previous Article:Asahi Kasei Pharma, CoTherix Conclude Licensing Agreement for Fasudil, Rho-kinase Inhibitor.
Next Article:AstraZeneca Japan Launches 24/7 Drug Alert Service.



Related Articles
Boning Up.
The nursing home crack: even the best care will be challenged by osteoporosis. (Caregiving).
Osteoprotegerin-receptor activator of nuclear factor-[kappa]B ligand ratio: a new approach to osteoporosis treatment?(Review Article)
Takara Bio Establishes Innovative Method to Commercially Produce Chalcones.
Takara Bio Sets up New Research Division at Institute for Protein Research, Osaka University.
Takara Bio, MolMed Announce That Phase I/II Clinical Trial of HSV-TK Gene Therapy Delivers Positive Results.
Takara Bio Confirms that Kelp-derived Fucoidan Inhibits Clot Formation.
Takara Bio Licenses FLT3 Gene Mutation Detection Method to InVivoScribe Technologies.
Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma.
Takara Bio Grants Transgenomic License for LA-PCR Technology.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles